Truist raised the firm’s price target on Insulet (PODD) to $390 from $365 and keeps a Buy rating on the shares. The company posted another strong beat and raise on broad Omnipod 5 strength, the analyst tells investors in a research note. The firm remains confident in Insulet’s prospects to sustain a well-above-average CAGR over the 2024-2028 period, Truist added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: